Cisplatin with Thoracic Chemoradiotherapy in Advanced NSCLC with Comorbid Disorders

Abstract

Lung cancer is the most common cancer in male gender worldwide. The primary treatment in patient with early stage of non-small cell lung cancer (NSCLC) is surgery. Five-year survival is about 15% for all stages. Seventy percent of patients are in the advanced stages at the time of diagnosis. Therefore, curative treatment can be offered to only 30% of the patients (Goldstraw et al., 2007). While chemotherapy administered in the advanced stage provides a 1-3 months benefit in terms of median survival, no change is observed in the patients’ quality of life (Spiro et al., 2004). A decline of 31% in 5-year survival rates was reported for patients with serious comorbidity, even in T1 disease. Most patients in NSCLC are locally advanced stage III or IV disease. Current newer generation agents such as vinorelbine, gemcitabine, paclitaxel and docetaxel may use for advanced NSCLC treatment. (Non-Small Cell Lung Cancer Collaborative Group, 1995; Schiller et al., 2002; Natukula et al., 2013). Paclitaxel or docetaxel plus cisplatin containing regimes are usually considered

4 Figures and Tables

Cite this paper

@inproceedings{Kiziltan2014CisplatinWT, title={Cisplatin with Thoracic Chemoradiotherapy in Advanced NSCLC with Comorbid Disorders}, author={Huriye Senay Kiziltan and Ayse Gunes Bayir and Didem Taştekin}, year={2014} }